Thus, we suspect that USP10 could reduce the DDR and stabilize mutp53 to promote tumor progression, and confers cisplatin resistance via HDAC6 in the mutp53 subset of NSCLC (Figure 1). The gene discussed is USP10; the disease is neoplasm.